Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shorty has a shit load they need to cover and was chasing through vert end of day Thursday and all Friday. No one was selling them squat! Just because they bring it down doesn’t mean we will sell them any!!!!! Zero from me!!!! They want shares bad like always really LOL! Buy em up before they do. Total loading zone here! Great posts all! Eom
Kristin is great at Paleo! What..she say..Several more clinics soon! :)) more and more and more hehe.
https://www.facebook.com/USStemCellInc/videos/2097478813860777/
Jack Nicklaus
“I'm not a doctor, but I think that stem cell is going to change... the direction of orthopedics, totally."
How long does he want to play golf? "As long as my stem cells allow me... Golf is a game of a lifetime, I hope to play for my lifetime".
https://www.google.com/amp/s/amp.cnn.com/cnn/2018/04/27/health/jack-nicklaus-stem-cell-therapy/index.html
John Salley success story
HUGE LOADING ZONE USRM! GRAB ANY AROUND THESE LEVELS AND SEND SHORTY A THANK YOU CARD!
We have gone up a bunch this year.
There is big support on the bottom of the pattern just in a hidden bid. It was there all the way up to mid .08’s from .under .02! You miss that?! Yes of course you want support but it’s there even though you CANT see it ;). You also don’t want 521 of us sitting there with our fingers up our asses waiting either. It’s a combo of both especially with a limited amount of strong shares holders! Oh and by the way go check naked short interest this week for those of you that don’t think it was a shorty. Once again It was a favor to accumulate shares. You think shorty made bunch on it. Hell no but the guy that gathered them will be doin’ okay down the road ya?! Probably the same one soakin’ all the way up ya?! Sigh...
We may just ride that 50 up until we pop...yeah ;)?!
Oh go tell the guy he’s good still sittin’ on the bid at .02 :))! GO $USRM Eom
https://otcshortreport.com/?index=USRM&action=view
Great post! Yes sirrrrr! All that for pennies. Writing is on the wall!
$USRM
US STEM CELL INC- Buy while cheap!
Future of Medicine is Regeneration!
Terrell Owens gets stem cell surgery
April 19, 2018
April Marks Parkinson’s Disease Awareness Month
World Parkinson’s Day was instituted on April 11th, 1997 to commemorate the birthday of Dr. James Parkinson, the man who first formally identified the disease nearly 200 years ago and penned the 1817 work—“An Essay on the Shaking Palsy.”
Today, the month of April marks the resurgence from winter, the beginning of allergy season, and most importantly, Parkinson’s Awareness Month.
According to the Parkinson’s Foundation, Parkinson’s disease currently impacts the lives of nearly one million people in the United States and five million people worldwide and can be attributed to a variety of genetic, environmental, and aging factors.
Parkinson’s disease is characterized as a chronic, progressive condition that involves the gradual degeneration of dopaminergic nerve cells in the brain.
While there are no objective tests to diagnose the disease, the current criteria for diagnosis are based on cardinal motor symptoms. These motor symptoms include tremor, slowness of movement, muscle stiffness, balance problems, and loss of short-term memory. Parkinson’s disease can manifest itself in the form of non-motor symptoms like depression, dementia, fatigue, sleep problems, digestive problems, loss of self-esteem, and stress, as well.
While there is no known cure for Parkinson’s disease, great strides are being made into the cause and treatment options, as evident by International Stem Cell Corporation’s (ISCO) newest research developments.
Recently, Parkinson’s disease patient and Australian real estate mogul Kevin Weeks underwent a clinical trial in which 30 million neural stem cells were implanted into 14 different parts of his brain, an unprecedented technology developed by ISCO scientists resulting in improved motor functions.
http://internationalstemcell.com/2018/04/19/april-marks-parkinsons-disease-awareness-month/
Not going away and yes dollars! Nice repost on market caps/pps A1 and totally agree with ya X and RR! Once again some are forgetting why we are down here too. Different company and booming industry now! This company will be the face of regenerative medicine imo and we have a market cap around 25 million! LOL LOL
$$$US STEM CELL INC FTW!
Don’t forget Lock your shares up on a GTC order for dollars with your broker. Buy buy buy! Long and strong folks! Future of medicine!
Yup buy and hold. Eom
Dollars $USRM! That’s amazing!
CANT is involved one way or another with the accumulation. Wether it is a hedge filling bids through CANT or CANT directly accumulating shares. IF THERE ISN’T a way around that 5% rule I guess I have to choose directly. CANT has been involved with the accumulation of a shit load of shares in the last six month to a year. They sit low on the pattern soaking and using fake walls and pepper tiny sells. They sure are good at hiding bids as well especially when “someone” is trying to scare the weak into the hidden bid. If you watch some market maker accumulation videos they say there is usually only one way to go but up if a MM is accumulating. Either way deep pockets have accumulated a shit load of shares here. Staying long myself. CANT seems to be showing they want this to ride the 50 up until it pops and prob will pop big. ALL IMO.
NEWS~Apr 18, 2018
International Stem Cell Corporation to Present Interim Clinical Results at the American Academy of Neurology
CARLSBAD, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that its Chief Scientific Officer, Russell Kern, PhD, will deliver a platform presentation on the Company's Parkinson's disease clinical trial at the American Academy of Neurology 70th Annual Meeting at the Los Angeles Convention Center in Los Angeles, CA.
Session Date: Tuesday April 24, 2018
Session title: Session S26: Movement Disorders: Parkinson's Disease Clinical Trials
Presentation Time: 3:42 PM
Presentation title: Interim Clinical Assessment of a Neural Stem Cell Based Therapy for Parkinson's Disease
About Parkinson's disease
Parkinson's disease (PD) is a degenerative disorder of the central nervous system mainly affecting the motor system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. Early in the course of the disease, the most obvious symptoms are movement-related; these symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise, with dementia commonly occurring in the advanced stages of the disease, and depression is the most common psychiatric symptom. Parkinson's disease is more common in older people, with most cases occurring after the age of 50.
Currently, medications typically used in the treatment of Parkinson's, L-DOPA and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and dopaminergic neurons continue to be lost, the drugs eventually become ineffective while at the same time frequently producing a complication marked by involuntary writhing movements. In 2013 PD resulted in about 103,000 deaths globally, up from 44,000 deaths in 1990.
About ISC-hpNSC®
International Stem Cell Corporation's proprietary ISC-hpNSC® consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSC® is a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are clear of any microbial and viral contaminants. Preclinical studies in rodents and non-human primates have shown improvement in Parkinson's disease symptoms and increase in brain dopamine levels following the intracranial administration of ISC-hpNSC®. ISC-hpNSC® provides neurotrophic support and cell replacement to the dying dopaminergic neurons of the recipient PD brain. Additionally, ISC-hpNSC® is safe, well tolerated and does not cause adverse events such as dyskinesia, systemic toxicity or tumors in preclinical models. International Stem Cell Corporation believes that ISC-hpNSC® may have broad therapeutic applications for many neurological diseases affecting the brain, the spinal cord and the eye.
About International Stem Cell Corporation
International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
Safe harbor statement
Statements pertaining to anticipated developments, expected results and timing of clinical studies, potential applications of ISC-hpNSC® to other diseases, progress of research and development initiatives, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products (including clinical trial results that differ from expectations based on earlier studies), regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Undervalued imo. Let’s get this train moving ;).
NEWS~Apr 18, 2018
International Stem Cell Corporation to Present Interim Clinical Results at the American Academy of Neurology
CARLSBAD, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that its Chief Scientific Officer, Russell Kern, PhD, will deliver a platform presentation on the Company's Parkinson's disease clinical trial at the American Academy of Neurology 70th Annual Meeting at the Los Angeles Convention Center in Los Angeles, CA.
Session Date: Tuesday April 24, 2018
Session title: Session S26: Movement Disorders: Parkinson's Disease Clinical Trials
Presentation Time: 3:42 PM
Presentation title: Interim Clinical Assessment of a Neural Stem Cell Based Therapy for Parkinson's Disease
About Parkinson's disease
Parkinson's disease (PD) is a degenerative disorder of the central nervous system mainly affecting the motor system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. Early in the course of the disease, the most obvious symptoms are movement-related; these symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise, with dementia commonly occurring in the advanced stages of the disease, and depression is the most common psychiatric symptom. Parkinson's disease is more common in older people, with most cases occurring after the age of 50.
Currently, medications typically used in the treatment of Parkinson's, L-DOPA and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and dopaminergic neurons continue to be lost, the drugs eventually become ineffective while at the same time frequently producing a complication marked by involuntary writhing movements. In 2013 PD resulted in about 103,000 deaths globally, up from 44,000 deaths in 1990.
About ISC-hpNSC®
International Stem Cell Corporation's proprietary ISC-hpNSC® consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSC® is a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are clear of any microbial and viral contaminants. Preclinical studies in rodents and non-human primates have shown improvement in Parkinson's disease symptoms and increase in brain dopamine levels following the intracranial administration of ISC-hpNSC®. ISC-hpNSC® provides neurotrophic support and cell replacement to the dying dopaminergic neurons of the recipient PD brain. Additionally, ISC-hpNSC® is safe, well tolerated and does not cause adverse events such as dyskinesia, systemic toxicity or tumors in preclinical models. International Stem Cell Corporation believes that ISC-hpNSC® may have broad therapeutic applications for many neurological diseases affecting the brain, the spinal cord and the eye.
About International Stem Cell Corporation
International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
Safe harbor statement
Statements pertaining to anticipated developments, expected results and timing of clinical studies, potential applications of ISC-hpNSC® to other diseases, progress of research and development initiatives, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products (including clinical trial results that differ from expectations based on earlier studies), regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
NEWS~Apr 18, 2018
International Stem Cell Corporation to Present Interim Clinical Results at the American Academy of Neurology
CARLSBAD, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that its Chief Scientific Officer, Russell Kern, PhD, will deliver a platform presentation on the Company's Parkinson's disease clinical trial at the American Academy of Neurology 70th Annual Meeting at the Los Angeles Convention Center in Los Angeles, CA.
Session Date: Tuesday April 24, 2018
Session title: Session S26: Movement Disorders: Parkinson's Disease Clinical Trials
Presentation Time: 3:42 PM
Presentation title: Interim Clinical Assessment of a Neural Stem Cell Based Therapy for Parkinson's Disease
About Parkinson's disease
Parkinson's disease (PD) is a degenerative disorder of the central nervous system mainly affecting the motor system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. Early in the course of the disease, the most obvious symptoms are movement-related; these symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise, with dementia commonly occurring in the advanced stages of the disease, and depression is the most common psychiatric symptom. Parkinson's disease is more common in older people, with most cases occurring after the age of 50.
Currently, medications typically used in the treatment of Parkinson's, L-DOPA and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and dopaminergic neurons continue to be lost, the drugs eventually become ineffective while at the same time frequently producing a complication marked by involuntary writhing movements. In 2013 PD resulted in about 103,000 deaths globally, up from 44,000 deaths in 1990.
About ISC-hpNSC®
International Stem Cell Corporation's proprietary ISC-hpNSC® consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSC® is a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are clear of any microbial and viral contaminants. Preclinical studies in rodents and non-human primates have shown improvement in Parkinson's disease symptoms and increase in brain dopamine levels following the intracranial administration of ISC-hpNSC®. ISC-hpNSC® provides neurotrophic support and cell replacement to the dying dopaminergic neurons of the recipient PD brain. Additionally, ISC-hpNSC® is safe, well tolerated and does not cause adverse events such as dyskinesia, systemic toxicity or tumors in preclinical models. International Stem Cell Corporation believes that ISC-hpNSC® may have broad therapeutic applications for many neurological diseases affecting the brain, the spinal cord and the eye.
About International Stem Cell Corporation
International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
Safe harbor statement
Statements pertaining to anticipated developments, expected results and timing of clinical studies, potential applications of ISC-hpNSC® to other diseases, progress of research and development initiatives, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products (including clinical trial results that differ from expectations based on earlier studies), regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
MEDICAL REVOLUTION!
Terrell Owen get stem cell surgery
Going Up. Buy any dip and feel lucky if you get filled because their will be a line. Face of Regenerative Medicine! We all know we shouldn’t be at these levels. Buy em up! #NotGettingMine!
It’s a short attack. Period.
Grabbed some myself.
Buy buy buy the dip. Going up. Future of medicine.
They are trying to short and scare shares out longs. Hold tight give them zero!
What really scares Big Pharma? People who learn how to CURE their own disease!
Tuesday, May 10, 2016?by Mike Adams, the Health Ranger?Tags: Big Pharma, disease prevention, repeat business
(NaturalNews) Big Pharma is terrified that you might discover a simple, powerful truth: You can prevent, reverse and CURE serious disease yourself! Your body is a powerful self-healing system, and your healing potential doesn't depend on doctors, drugs or surgery.
In my new podcast (see links below), I cover all this and more:
• What is Big Pharma terrified of?
• They are terrified of natural medicine because it's safer, more affordable and works better than pharmaceuticals!
• Big Pharma pays off journalists, bribes doctors and funds online mercenaries to attack proponents of natural medicine.
• They even attack anti-cancer foods and nutrition!
• They attack acupuncture, chiropractic, meditation, breastfeeding and much more.
• The real reason the medical establishment despises natural medicine is because it doesn't cause SIDE EFFECTS that bring huge revenues to doctors, hospitals and drug companies! (They feed off the repeat cycle of disease and sickness caused by the medical system itself!)
• We are living in an era where knowledge is monopolized by a power structure that wants the people to remain illiterate and ignorant about natural medicine.
• Big Pharma feeds off ignorance and disease. This is their profit model. So they try to censor books, films, websites and knowledge.
• More people are waking up and realizing Big Pharma is a criminal cartel, created to HARVEST profits off your body.
• Big Pharma is engaged in abuses of human rights, medical experimentation on children, and repeated medical ethics violations.
• "If you're in the business of selling drugs to sick people, the only way you keep making money is to keep people sick."
• Drug companies would NEVER develop pills that actually worked to halt disease... it would put them out of business!
• "There is no corporate entity that will deliberately commit financial suicide."
• Drug companies created the massive, global "superbug" epidemic.
• The drug companies have financially infiltrated government, medical schools, academia and the mainstream media.
• BY DESIGN, drugs never solve health problems. Otherwise, there would be no repeat sales.
• The treatment of one disease causes another disease, which then requires MORE treatment.
• People on multiple pharmaceuticals are the LEAST healthy people in society. They almost never get better!
• Big Pharma FAKES the clinical trial data to produce whatever "scientific" results they want.
• All people who promote disease prevention are TARGETED by Big Pharma to be slandered, censored and destroyed.
• The only person who has a vested interest in YOUR health is YOU!
• The pharmaceutical cartels don't want you to have a CHOICE in your own health outcome.
• I promote knowledge, wisdom and empowerment. Freedom of choice. Disease prevention. The use of food as medicine to PREVENT disease.
http://www.naturalnews.com/053967_Big_Pharma_disease_prevention_repeat_business.html
They want your shares bad real bad. Also big pharma is pissing their pants as their bank acct gets drained!
Haha! Another hit piece! Laughable!! F you big pharma and manipulators!!
Yes sir! ;$USRM #NotGettingMyShares
I really like that! Yeah this company is creating a web of revenue streams. Very very exciting. #retirementstock $USRM
300k and 49% plus 5%! I like that deal! Sounds like a money maker there!! Can’t wait for the next Q already. I think the Q last year was beginning of May! Going to be a huge year!
In the 10-k:
On January 30, 2018, Greg Knutson, a director of the Company (“Knutson”) and the Company agreed to open and operate a r egenerative medicine/cell therapy clinic providing cellular treatments for patients afflicted with neurological, autoimmune, orthopedic and degenerative diseases in Florida. To that end, U.S. Stem Cell Clinic of The Villages LLC (the “LLC”) was formed January 30, 2018. Knutson provided the Company with the sum of Three Hundred Thousand Dollars ($300,000) (the “Investment”) to be utilized for the formation and initial operation of the LLC. Currently, Knutson holds a 51% Member Interest in the LLC and the Company holds a 49% Member Interest. The Company will provide operating assistance as well as management services, the latter to be compensated at fee of five percent (5%) of the net revenues.
We are very excited to announce that the groundbreaking stem cell documentary, The Healing Miracle, is re-launching TOMORROW!
Great chart. Thanks
Under business Strategy:
A fundamental shift in venture capital investment strategies where, management believes, financial sponsorship is now directed toward commercial or near commercial enterprises has required U.S. Stem Cell to adapt its mission combining immediate revenue generating opportunities with longer-term development programs. Accordingly, U.S. Stem Cell has developed a multifaceted portfolio of revenue generating products and services in its US Stem Cell Training, Vetbiologics, and US Stem Cell Clinic, operating divisions that will, if successful, financially support its clinical development programs. Our goal is to maximize shareholder value through the generation of short-term profits that increase cash in-flows and decrease the need venture financings – a modern biotechnology company development strategy.
In the 10-k under business strategy:
We will continue to evaluate and act upon opportunities to increase our top line revenue position and that correspondingly increase cash in-flows. These opportunities include but are not limited to the development and marketing of new products and services, mergers and acquisitions, joint ventures, licensing deals and more.
Awesome Revs and similar o/s! Sweet! Good job USRM!
Sooo BULLISH! Check barchart! Buy buy buy #GoLongFTW
#FutureofMedicine
There’s a Potential Breakout on US Stem Cell Inc (OTCMKTS:USRM)
By Jermaine Farmer - April 3, 2018
US Stem Cell Inc (OTCMKTS:USRM) is a stock on the move in a major way. USRM has been trending sharply higher over the past four months, breaking above major moving averages and accelerating on its rounded upward trajectory in what looks like the beginnings of a potential parabolic advance, from a technical perspective. The trend is now facing up to a key technical hurdle: a gap-fill of the large drop last seen down through the $0.08/share level back in June of 2017. That gap has gone unfilled until last month when the level was tested and rejected. Now, shares are pushing back up to test it again as a possible breakout trigger.
The trend has been pushed along by core tech items such as its recent announcement that it has successfully demonstrated a 99 percent reduction in-human of the severity of psoriasis using a patient’s autologous stem cells. According to the release, “the scientific paper, which is authored by USRM Chief Science Officer Dr. Kristin Comella and her USRM colleagues, is published in the International Medical Case Reports Journal, 2018:11 59-64. To the best of USRM management’s knowledge, this is the first result in the world published using stromal vascular fraction (SVF) and autologous stem cells in the successful treatment of psoriasis.”
US Stem Cell Inc (OTCMKTS:USRM) bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the body’s own healing potential, we may be able to reverse damaged tissue to normal function.
The company’s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
USRM is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.
According to company materials, “USRM is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern
As noted above, USRM shares have been warming up and approaching potential red-hot status as the stock moves to test key resistance areas in its recent upward trend. We have been seeing some signs that its core R&D IP narrative has been progressing, powering the move.
“This is a breakthrough for the more than 7 million Americans suffering from psoriasis, and is another example of how a patient’s own stem cells offer healing modalities for autoimmune conditions,” said Dr. Comella. “Although we require additional studies to further develop more extensive protocol in treating patients with this condition, this is a benchmark indicating there is significant reason to believe the use of autologous stem cells is beneficial in combating this disease.”
Recent action has seen 73% added to share values of the name over the past month of action. Furthermore, the name has witnessed a pop in interest, as transaction volume levels have recently pushed 78% over the long run average.
Earning a current market cap value of $28M, USRM has a stash ($957K) of cash on the books, which compares with about $3.2M in total current liabilities. USRM is pulling in trailing 12-month revenues of $5M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 106.4%. This may be a very interesting story and we will look forward to updating it again soon. Sign-up for continuing coverage on shares of $USRM stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $USRM, either long or short, and we have not been compensated for this article.
Newest Clinic Opens Today at The Villages in Central Florida
Posted by U.S. Stem Cell, Inc
SUNRISE, FL – April 9, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the opening its first USRM clinic in North Central Florida.
The U.S. Stem Cell Clinic of The Villages will offer alternatives to chronic pain management using USRM’s proprietary AdipoCell TM product in a minimally invasive procedure utilizing a patient’s own (autologous) stem cells. Medical director for the clinic will be Dr. Rosemary Daly, an interventional spine/pain management physician who is board certified in Anesthesiology and Pain Medicine. Dr. Daly, who graduated from the New York College of Osteopathic Medicine, is also medical director for the Regenerative Wellness Clinic (RWC) in West Palm Beach, which is also in the USRM network of stem cell treatment centers.
“Expansion of our regenerative healing centers to The Villages is an opportunity to directly serve an active community that is very proactive about seeking ways to increase their quality of life,” said Dr. Kristin Comella, USRM’s Chief Science Officer. “We look forward to serving this vibrant community by offering holistic stem cell therapy for neurological, autoimmune, orthopedic and degenerative conditions.”
“Our vision at USRM has always been to expand access of autologous stem cell treatments to as many people as possible,” said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. “Now that we are seeing a steady increase in demand for stem cell therapy, which has driven our progress in reaching milestones that allow for growth, we are ready to continue expanding our network of clinics. The clinic at The Villages represents that next step.”
USRM has been instrumental in performing more than 10,000 stem cell procedures in the past 19 years for a variety of indications. USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has a growing network of 288 physicians and clinics utilizing the USRM technologies, protocols and products. Dr. Comella continues to enhance USRM’s visibility worldwide for autologous stem cell treatments, as well as developing and bringing USRM’s proprietary Adipocell TM product to market: a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.
Dr. Comella is also well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. Most recently, she presented a summary of peer-reviewed publications at the Academy of Regenerative Practices Conference in Weston, Florida.
U.S. Stem Cell’s novel advancements in stem cell therapy, in managements’ opinion, could be a significant alternative to the explosive opioid crisis in America — a direct results of America’s failed attempt at pain management. According to The New York Times, drug overdose is now the leading cause of death in the United States for patients under the age of 50, while the October 15, 2017, edition of 60 Minutes reports that the opioid crisis has claimed 200,000 lives in the United States over the past few decades.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry
specializing in physician training and certification and stem cell products including its lead
product Adipocell TM , as well as veterinary stem cell training and stem cell banking and creation
and management of stem cell clinics. To management’s knowledge, USRM has completed more
clinical treatments than any other stem cell company in the world.
Terrell Owen get stem cell surgery
Yes there are and It’s coming fast! Cats out the bag there’s no stopping it. I’ll reiterate what the brilliant Dr. Murphy (Yeah the guy with something like 17 medical patents etc) said in the docuseries the healing miracle “Regenerative medicine will change medicine like antibiotics did”.
Terrell Owen get stem cell surgery
To many bread crumbs tisk tisk
Another huge revenue stream added! Seem like every month there is another one! The speed of growth here is incredible actually. Do your own DD!
Newest Clinic Opens Today at The Villages in Central Florida
Posted by U.S. Stem Cell, Inc
SUNRISE, FL – April 9, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the opening its first USRM clinic in North Central Florida.
The U.S. Stem Cell Clinic of The Villages will offer alternatives to chronic pain management using USRM’s proprietary AdipoCell TM product in a minimally invasive procedure utilizing a patient’s own (autologous) stem cells. Medical director for the clinic will be Dr. Rosemary Daly, an interventional spine/pain management physician who is board certified in Anesthesiology and Pain Medicine. Dr. Daly, who graduated from the New York College of Osteopathic Medicine, is also medical director for the Regenerative Wellness Clinic (RWC) in West Palm Beach, which is also in the USRM network of stem cell treatment centers.
“Expansion of our regenerative healing centers to The Villages is an opportunity to directly serve an active community that is very proactive about seeking ways to increase their quality of life,” said Dr. Kristin Comella, USRM’s Chief Science Officer. “We look forward to serving this vibrant community by offering holistic stem cell therapy for neurological, autoimmune, orthopedic and degenerative conditions.”
“Our vision at USRM has always been to expand access of autologous stem cell treatments to as many people as possible,” said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. “Now that we are seeing a steady increase in demand for stem cell therapy, which has driven our progress in reaching milestones that allow for growth, we are ready to continue expanding our network of clinics. The clinic at The Villages represents that next step.”
USRM has been instrumental in performing more than 10,000 stem cell procedures in the past 19 years for a variety of indications. USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has a growing network of 288 physicians and clinics utilizing the USRM technologies, protocols and products. Dr. Comella continues to enhance USRM’s visibility worldwide for autologous stem cell treatments, as well as developing and bringing USRM’s proprietary Adipocell TM product to market: a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.
Dr. Comella is also well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. Most recently, she presented a summary of peer-reviewed publications at the Academy of Regenerative Practices Conference in Weston, Florida.
U.S. Stem Cell’s novel advancements in stem cell therapy, in managements’ opinion, could be a significant alternative to the explosive opioid crisis in America — a direct results of America’s failed attempt at pain management. According to The New York Times, drug overdose is now the leading cause of death in the United States for patients under the age of 50, while the October 15, 2017, edition of 60 Minutes reports that the opioid crisis has claimed 200,000 lives in the United States over the past few decades.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry
specializing in physician training and certification and stem cell products including its lead
product Adipocell TM , as well as veterinary stem cell training and stem cell banking and creation
and management of stem cell clinics. To management’s knowledge, USRM has completed more
clinical treatments than any other stem cell company in the world.